Literature DB >> 22327362

Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?

Jack Antel1, Samson Antel, Zografos Caramanos, Douglas L Arnold, Tanja Kuhlmann.   

Abstract

Multiple sclerosis (MS), the most frequent demyelinating disease, is characterized by a variable disease course. The majority of patients starts with relapsing remitting (RR) disease; approximately 50-60% of these patients progress to secondary progressive (SP) disease. Only about 15% of the patients develop a progressive disease course from onset, termed primary progressive multiple sclerosis (PPMS); the underlying pathogenic mechanisms responsible for onset of the disease with either PPMS or relapsing remitting multiple sclerosis (RRMS) are unknown. Patients with PPMS do not show a female predominance and usually have a later onset of disease compared to patients with RRMS. Monozygous twins can be concordant or discordant for disease courses indicating that the disease course is not only genetically determined. Primary progressive multiple sclerosis and secondary progressive multiple sclerosis (SPMS) share many similarities in imaging and pathological findings. Differences observed among the different disease courses are more of a quantitative than qualitative nature suggesting that the different phenotypes are part of a disease spectrum modulated by individual genetic predisposition and environmental influences. In this review, we summarize the knowledge regarding the clinical, epidemiological, imaging, and pathological characteristics of PPMS and compare those characteristics with RRMS and SPMS.

Entities:  

Mesh:

Year:  2012        PMID: 22327362     DOI: 10.1007/s00401-012-0953-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  69 in total

1.  Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.

Authors:  Jean-Baptiste Davion; M Cambron; E Duhin; A Chouraki; A Lacour; P Labauge; C Carra; X Ayrignac; P Vermersch
Journal:  J Neurol       Date:  2016-05-09       Impact factor: 4.849

Review 2.  New and emerging immune-targeted drugs for the treatment of multiple sclerosis.

Authors:  Alan M Palmer
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

3.  Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia.

Authors:  Aniruthan Renukanthan; Richard Quinton; Benjamin Turner; Peter MacCallum; Leighton Seal; Andrew Davies; Richard Green; Jane Evanson; Márta Korbonits
Journal:  Endocrine       Date:  2015-03-05       Impact factor: 3.633

4.  Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).

Authors:  Uwe K Zettl; Thomas Henze; Ute Essner; Peter Flachenecker
Journal:  Eur J Health Econ       Date:  2013-12-01

Review 5.  Oxidative/Nitroxidative Stress and Multiple Sclerosis.

Authors:  Tobore Onojighofia Tobore
Journal:  J Mol Neurosci       Date:  2020-08-07       Impact factor: 3.444

Review 6.  Treatment trials in progressive MS--current challenges and future directions.

Authors:  Marcus W Koch; Gary Cutter; Peter K Stys; V Wee Yong; Luanne M Metz
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

Review 7.  Relapsing and progressive forms of multiple sclerosis: insights from pathology.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

8.  Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Authors:  Jordana Hughes; Vilija Jokubaitis; Alessandra Lugaresi; Raymond Hupperts; Guillermo Izquierdo; Alexandre Prat; Marc Girard; Pierre Duquette; Francois Grand'Maison; Pierre Grammond; Patrizia Sola; Diana Ferraro; Cristina Ramo-Tello; Maria Trojano; Mark Slee; Vahid Shaygannejad; Cavit Boz; Jeanette Lechner-Scott; Vincent Van Pesch; Eugenio Pucci; Claudio Solaro; Freek Verheul; Murat Terzi; Franco Granella; Daniele Spitaleri; Raed Alroughani; Jae-Kwan Jun; Adam Fambiatos; Anneke Van der Walt; Helmut Butzkueven; Tomas Kalincik
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

Review 9.  Promoting remyelination: utilizing a viral model of demyelination to assess cell-based therapies.

Authors:  Brett S Marro; Caroline A Blanc; Jeanne F Loring; Michael D Cahalan; Thomas E Lane
Journal:  Expert Rev Neurother       Date:  2014-10       Impact factor: 4.618

Review 10.  Exploring Wellness Interventions in Progressive Multiple Sclerosis: an Evidence-Based Review.

Authors:  Myriam Venasse; Thomas Edwards; Lara A Pilutti
Journal:  Curr Treat Options Neurol       Date:  2018-04-10       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.